{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.1","upperLimit":"8.1","value":"7.1"},{"groupId":"OG001","lowerLimit":"4.4","upperLimit":"7.1","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"description":"DOR is defined as the time from the first determination of an objective response until the first documentation of progression assessed by the investigator per RECIST v1.1 or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method.\n\nPrimary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received tislelizumab 200 mg administered IV on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons.","id":"OG000","title":"Tislelizumab + Chemotherapy"},{"description":"Participants received placebo administered IV on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons.","id":"OG001","title":"Placebo + Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Participants in the ITT Analysis Set with an objective response","reportingStatus":"POSTED","timeFrame":"From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}